“The next new $1trn stock will be…”

There are a very select few stocks that have seen their market cap exceed $1trn. And those that bought shares before that milestone will be very happy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The flag of the United States of America flying in front of the Capitol building

Image source: Getty Images

Since The Motley Fool’s mission statement is to make the world smarter, happier and richer, we asked some of our freelance writers which US stocks they think might be next to crack the $1trn threshold — potentially making shareholders very happy indeed!

Berkshire Hathaway

What it does: Warren Buffett’s diversified holding company uses an insurance float model to invest in dozens of businesses.

By Charlie CarmanBerkshire Hathaway (NYSE:BRK.A) (NYSE:BRK.B) has broken the $700bn market capitalisation barrier, but it’s never reached the trillion-dollar threshold. I think that’s only a matter of time. As I write, the company would need to deliver a 36% share price gain to achieve this landmark.

From 1965 to 2022, Berkshire Class A stock achieved a 19.8% compound annual growth rate. Returns have slowed since the turn of the millennium, but the annual average remains firmly in double digits.

Recent results have been encouraging. In the first quarter, Berkshire posted a $35.5bn profit and accelerated its share repurchases, buying back $4.4bn of its own stock.

A major risk facing the company is the potential loss of investor confidence that could result from its CEO’s looming departure. After all, Buffett is 92.

However, his successor Greg Abel has already taken on many responsibilities, suggesting the handover could be less problematic than some fear.

Charlie Carman owns shares in Berkshire Hathaway. 

Berkshire Hathaway

What it does: Berkshire Hathaway is a diversified conglomerate that operates in sectors including insurance and retail and owns a stock portfolio.

By Christopher Ruane. The famed investor Warren Buffett has built Berkshire Hathaway over the course of decades.

Since taking the company over in 1965, Buffett has achieved a compounded annual gain of 19.8% in its per-share market value.

Some years are markedly better than others. In general, I think the defensive nature of many Berkshire businesses means that it can do well when the wider market stumbles. In 2007, for example, its compounded annual gain was 28.7% while the benchmark S&P 500 only achieved 5.5%.

The economy looks weak again to me, but one big difference is Berkshire’s massive position in Apple. If tech stocks including Apple fall, that could hurt Berkshire’s share price.

But I think the company’s broadly defensive asset base and Buffett’s steady hand on the tiller could help Berkshire ride out the next storm well. Its shares have risen 81% in five years and today the market capitalisation is $736bn.  

Christopher Ruane does not own shares in any of the companies mentioned.

Eli Lilly

What it does: Eli Lilly is a global healthcare company with products spanning oncology, immunology, diabetes and neurology.

By Ben McPoland. I think biopharma giant Eli Lilly (NYSE: LLY) could become the newest $1trn stock. Its market cap of $435bn already makes it one of the largest companies in the world.

The firm has a packed late-stage pipeline of potential blockbusters. One is its Alzheimer’s treatment, donanemab,which has successfully slowed memory and thinking decline in a rigorous phase 3 trial.

A second is Mounjaro, which is a medicine already used by people with type 2 diabetes. It is currently being assessed by US regulators and the NHS as a repositioned treatment for weight loss.

Needless to say, a proven and safe treatment for obesity (which is a global health issue) could be a huge deal for the company. Indeed, some analysts think it could become the biggest selling drug ever. And it could be approved by the end of this year. 

One risk is that this huge potential is already priced into the stock, with its trailing P/E of 72. Any disappointing regulatory news could hit the share price hard.  

Ben McPoland does not own shares in Eli Lilly.

The Motley Fool UK has recommended Apple. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£5,000 invested in red-hot UK growth stock ITM Power 5 days ago is now worth…

UK stock ITM Power is getting a lot of attention at the moment. Because the company just partnered with one…

Read more »

A pastel colored growing graph with rising rocket.
Investing Articles

£20,000 invested in Barclays shares 2 years ago is now worth…

Barclays shares have surged 134% since April 2024 — but the bank’s strong fundamentals, huge cash generation, and valuation gap…

Read more »

ISA coins
Investing Articles

How big must an ISA be to aim for a £15,000+ a year second income?

This FTSE investment gem could generate huge returns over time in a Stocks and Shares ISA, exempt from income and…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

Down 17% to under £5! Here’s why this overlooked FTSE 250 defence gem looks a bargain anywhere below £6.12

FTSE 250 defence firm QinetiQ is stacking billions in long‑cycle contracts, yet its share price looks fast asleep — and…

Read more »

DIVIDEND YIELD text written on a notebook with chart
Investing Articles

A 9% dividend yield! 1 dirt-cheap FTSE 100 passive income gem to snap up today?

This FTSE stock offers huge passive income, looks deeply undervalued, and has strong forecast earnings growth -- making it too…

Read more »

Thoughtful man using his phone while riding on a train and looking through the window
Growth Shares

What are the best growth shares to try and double your money?

Jon Smith points out several key characteristics of growth shares to differentiate the good from the bad, and highlights one…

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

I asked ChatGPT for the best FTSE 100 stock for total returns in 2026, and guess what it said…

Are AI chatbots any better than humans at digging out the best value FTSE 100 stocks to consider buying? They…

Read more »

UK money in a Jar on a background
Investing Articles

How much should someone invest to target a £100 weekly second income?

Bringing in a second income can spell the difference between comfort or crisis when an emergency happens. Mark Hartley breaks…

Read more »